Cannabis Law Report

NOVEMBER 5, 2019

Cabot Wealth Management Inc increased its stake in Gw Pharmaceuticals Plc (GWPH) by 34.2% The institutional investor held 20,865 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $3.60M, up from 15,548 at the end of the previous reported quarter. based on its latest 2019Q2 regulatory filing with the SEC.

Pharmaceutical 45

Pharmaceutical Epilepsy Treatment Medicine 45

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Veriheal

JULY 26, 2023

Georgia medical cannabis patients will soon have greater access to treatment as cannabis oil will be sold in many more pharmacies. In 2019, Georgia’s General Assembly passed Georgia’s Hope Act, which legalized the regulated cultivation of marijuana in the State. Eligible patients were granted access to low-THC marijuana oil.

Oil 98

Oil Patients Access THC 98

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Veriheal

SEPTEMBER 27, 2021

Medical cannabis has been legal in the nation for almost three years—so why are MS patients struggling to access the treatment? 1, MS Society UK posted on Twitter , “Getting the treatment you need shouldn’t be a game of chance. It’s this line of thought that contributed to the drive for launching a campaign. . ApprovedButDenied.

Treatment 98

Treatment Patients Access Research and Development 98

The Blunt Truth

OCTOBER 3, 2019

In Connecticut , meanwhile, the state may add chronic pain to the list of conditions eligible for treatment with medical marijuana. GW Pharmaceuticals and Montefiore Medical Center in New York are teaming up to study the use of a cannabis compound on autism.

Chronic Pain 77

Chronic Pain Hemp DEA Programs 77

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. 30 May 2019. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

NORML

JULY 1, 2019

Three new laws intended to expand patient access to and the therapeutic value of Virginia’s medical cannabis program take effect July 1, 2019. “Virginia is moving in the right direction to ensure patients and doctors can choose treatments that are right for them. ” Virginia Senator Siobhan Dunnavant.

Law 257

Law Patients Access Oil 257

NORML

NOVEMBER 8, 2019

This year, we can and must succeed in passing this essential legislation and protecting the rights of veterans to access medical treatment and serving those who served us. We know medical marijuana can be an effective and safe treatment for veterans and it is time to stop making them seek private, out-of-network physicians to access it.

Access 200

Access Marijuana Treatment Legislation 200

Cannabis Law Report

JUNE 24, 2021

Luxembourg decrimininalised the sale and prescription of medicinal cannabis for the treatment of chronic pain, cancer, neuro-degenerative, and other chronic diseases starting August 2018, with approved products sold out of the country’s hospital pharmacies. Of the numerous delayed orders, the longest was 60 days in 2020, for a THC product.

Medicine 104

Medicine Chronic Pain Treatment Patients 104

Cannabis Law Report

JULY 7, 2022

January 2019. filed a petition requesting inter partes review of claims 1-13 of GW Pharmaceutical Ltd.’s s patent directed to the use of cannabinoids, including cannabidiol (“CBD”), in the treatment of certain types of epilepsy. GW Pharma Limited and Otsuka Pharmaceutical Co., Insys Development Company, Inc.

Epilepsy 52

Epilepsy Pharmaceutical Treatment Cannabinoids 52

Canna Law Blog

NOVEMBER 14, 2021

Mind Medicine, also known as MindMed, filed an application to register the MINDMED mark in 2019. The application includes goods in Class 5, specifically, “Pharmaceuticals for the treatment of mental health conditions; pharmaceuticals for the treatment of depression; psychoactive medicines; psychedelic medicines.”

Pharmaceutical 72

Pharmaceutical Treatment Edibles Medicine 72

CannaMD

FEBRUARY 19, 2020

Most recently, a study released in the fall of 2019 reveals some of the specific ways in which compounds within marijuana work to block fear-related memories. Before getting to this news, let’s take a minute to review some of the prior research supporting marijuana for the treatment PTSD. How CBD Targets Fear-Related Memories.

CBD 92

CBD Pharmaceutical Research and Development Conditions 92

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. billion in 2019. billion in 2019. Over the next several years, the psychedelics industry is expected to grow at a compound annual growth rate of 16.3

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Veriheal

JUNE 19, 2023

The psychedelic drugs here include LSD, MDMA, psilocybin, ketamine, and ayahuasca, which are in high demand for mental health treatment and other therapeutic reasons. There was a corresponding increase in the suicide rate, which increased the demand for psychedelic drugs for necessary treatment.” billion in the next six years.

Therapy 109

Therapy Treatment Patients Policy 109

Veriheal

OCTOBER 13, 2020

Cannabis has been identified as an effective alternative treatment for some gastrointestinal disorders…but does that include IBD and IBS? . Diet is used as the primary treatment. . Dronabinol is commonly used as a treatment in cancer patients due to the fact that it can decrease gut transit and increase colon compliance.

Digestion 123

Digestion Treatment Conditions Research and Development 123

The Cannigma

JANUARY 24, 2021

The team at the University of Queensland soon noticed that one form of CBD was particularly adept at breaking down MRSA’s biofilms, the slimy structural supports that help the bacteria survive antibiotic treatments. The researchers also observed one CBD solution eliminate Neisseria gonorrhoeae bacteria, which cause gonorrhea.

CBD 125

CBD Clinical Trials Treatment Pharmaceutical 125

Veriheal

JULY 12, 2021

According to data on Healthy Place , treatment for PTSD is typically accommodated for the general public, of who the vast majority have not experienced military combat. At this time, there is little in the way for combat-related PTSD treatment specifically. But veterans utilize general PTSD treatment and still experience recovery.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Veriheal

NOVEMBER 17, 2020

Back in 2019, it seemed as though advocates might have had things going in their favor to add Autism Spectrum Disorder and anxiety to this list of qualifying conditions. He ran clinical trials for big pharma’s GW Pharmaceuticals research division on Epidiolex. However, that forward momentum was short-lived.

Conditions 98

Conditions Research and Development Pharmaceutical Clinical Trials 98

CannaMD

NOVEMBER 22, 2020

Unfortunately, most traditional pharmaceutical options are distinctly lacking due to side effects, as well as a bit of trepidation (although Botox, one current treatment option for migraines, has gained popularity). Researchers also found that cannabis oil was more effective than cannabis flower as a treatment option.

Marijuana 116

Marijuana Treatment Patients Cannabinoids 116

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. Why Do MMJ Patients Use Cannabis?

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

JUNE 2, 2021

and has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.” In 2019, the Idaho State Board of Pharmacy issued an advisory document confirming the same. Pharmaceutical Grade CBD Oil. Idaho Code § 37-2701 et seq. Idaho Code § 37-2704.

Law 103

Law Marijuana Oil Pharmaceutical 103

Cannabis Law Report

MAY 12, 2022

“There are hundreds of millions of people worldwide that are suffering with depression, and almost 70% of them aren’t helped on current antidepressant or psychotherapy treatments,” Davis said. Davis came to OSU in 2019 with a background in researching psychedelics at Johns Hopkins University.

Therapy 69

Therapy Research and Development Treatment Pharmaceutical 69

Veriheal

FEBRUARY 28, 2022

The need for effective treatment is not only important for restoring one’s health but also for returning functioning and quality of life. Current antidepressants can have some serious side effects, as most pharmaceuticals do. A New Kind of Depression Treatment. In 2019, the U.S.

Research and Development 98

Research and Development Treatment Therapy Environment 98

Cannabis Law Report

JULY 30, 2019

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. The US approval of Zogenix’s Fintepla, a potential competitor for GW’s drug, has been delayed but still lo… The European Pharmaceutical Review reports.

Epilepsy 40

Epilepsy Pharmaceutical Medicine Treatment 40

The Cannigma

JUNE 19, 2022

In 2019, the Constitutional Court of Colombia overruled the ban on public consumption. Access is restricted to pharmaceutical products, but patients can also grow their own plants if they prefer the raw material. It can be challenging to find a doctor willing to prescribe cannabis treatments or to find a clinic to fill a prescription.

Legalization 97

Legalization Decriminalization Research and Development Consumption 97

Cannabis Law Report

JANUARY 16, 2020

The European Medicinal Cannabis Association (EUMCA), the newly formed Brussels-based industry body which advocates for European evidence-based policy to improve patient access to high-quality cannabis treatment, has announced the appointment of Professor Jones, CBE, FMedSci, as its new Chairman. Professor Jones.

Medicine 59

Medicine Research and Development Pharmaceutical Policy 59

CannaTech

JANUARY 16, 2019

Pharmaceutical grade cannabis is relatively new in parts of the world. Patients, and their treatment, therefore, are the priority. Treatment options may be limited by government-approved imports, a practitioner’s prescription or pharmacy stock. It is not a story about profiting off of people.

Access 89

Access Patients Pharmaceutical Education 89

Cannabis Law Report

FEBRUARY 5, 2020

The success of our pharmaceutical arm Eco Equity over the past 18 months shows there is appetite for investment in the industry. The cannabis market is the fastest-growing market of 2019, proving its unstoppable growth and obvious attraction for investors. “We Successful acquisitions. Source: [link].

Seed-To-Sale 59

Seed-To-Sale Pharmaceutical Medicine Cultivation 59

Cannabis Law Report

JANUARY 26, 2022

As public sentiment has changed—driven in large part by anecdotal accounts of psilocybin’s effectiveness as a treatment for PTSD as well as treatment-resistant depression and anxiety —several jurisdictions have begun removing barriers to psilocybin use through deprioritization, decriminalization, and full legalization.

Legalization 52

Legalization Treatment Decriminalization Pharmaceutical 52

Cannabis Law Report

JUNE 25, 2021

Major players in the global skin cancer drugs market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, and Sun Pharmaceutical Industries Ltd. In April 2019, Bristol-Myers Squibb acquired Celgene for $74 billion. According to the American Academy Of Dermatology, 192,310 new cases of Melanoma type skin cancer were expected in 2019.

Research and Development 84

Research and Development Therapy Pharmaceutical Clinical Trials 84

Puff Puff Post

MARCH 21, 2019

New Breakthrough Treatment for Opiate Addiction with a Unique Combination of Specific Detox Medications, Vivitrol and Reduction of Pressure to the Brain Stem. According to Neurologist & Addiction Medicine Specialist Dr. Russell Surasky, Tips on New and Advanced System of Addiction Treatment Showing Great Success.

Treatment 18

Treatment Research and Development Patients Pharmaceutical 18

Cannabis Law Report

DECEMBER 14, 2019

According to Australian marijuana research firm FreshLeaf Analytics, during Q3 of 2019, 76 new products were introduced in the market, up from 54 in Q1. Clinical stage CBD company Botanix Pharmaceuticals (ASX: BDA ) works on using cannabidiol (CBD) in its treatment of skin conditions including acne, psoriasis, dermatitis and rosacea.

Pharmaceutical 98

Pharmaceutical Patients Clinical Trials Hemp 98

Cannabis Law Report

DECEMBER 9, 2019

Although official uses (outside of treatment for childhood epilepsy) have not been officially approved by the FDA, early results from research has resulted in consumers flocking to the compound of their own accord and at their own risk. Natural remedies are very appealing to most pet owners.

Pets 59

Pets CBD Research and Development Epilepsy 59

Veriheal

FEBRUARY 11, 2021

The objective of the survey published in December 2020 explored “ the effect that medical cannabis has on prescription opioid medication usage for the treatment of chronic pain at three medical cannabis practice sites ”. The Effect of Medical Cannabis on Prescription Opioids.

Chronic Pain 85

Chronic Pain Patients Clinical Trials Treatment 85

Cannabis Law Report

FEBRUARY 18, 2020

JSP Pharmaceutical Manufacturing Thailand is teaming up with Rajamangala University of Technology Thanyaburi (RMUTT) to conduct research on sleeping pills made with cannabis. “The collaboration with RMUTT will develop and conduct research for commercial purposes — local sales and exports for insomnia treatment.”

Research and Development 59

Research and Development Sleep Treatment Medicine 59

Cannabis Law Report

FEBRUARY 28, 2022

12, 2019), [link] [ [link] ]. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Leger, Psychedelics as an Emerging Novel Intervention in the Treatment of Substance Use Disorder: A Review , 47 MOLECULAR BIOLOGY REP. Mitchell et al.,

Research and Development 52

Research and Development Therapy Law Clinical Trials 52